73 related articles for article (PubMed ID: 27299748)
1. Rho GTPases: RAC1 polymorphisms affected platinum-based chemotherapy toxicity in lung cancer patients.
Zou T; Yin J; Zheng W; Xiao L; Tan L; Chen J; Wang Y; Li X; Qian C; Cui J; Zhang W; Zhou H; Liu Z
Cancer Chemother Pharmacol; 2016 Aug; 78(2):249-58. PubMed ID: 27299748
[TBL] [Abstract][Full Text] [Related]
2. Effect of transporter and DNA repair gene polymorphisms to lung cancer chemotherapy toxicity.
Chen J; Wu L; Wang Y; Yin J; Li X; Wang Z; Li H; Zou T; Qian C; Li C; Zhang W; Zhou H; Liu Z
Tumour Biol; 2016 Feb; 37(2):2275-84. PubMed ID: 26358256
[TBL] [Abstract][Full Text] [Related]
3. Genetic Variants of the MDM2 Gene Are Predictive of Treatment-Related Toxicities and Overall Survival in Patients With Advanced NSCLC.
Qian J; Liu H; Gu S; Wu Q; Zhao X; Wu W; Wang H; Wang J; Chen H; Zhang W; Wei Q; Jin L; Lu D
Clin Lung Cancer; 2015 Sep; 16(5):e37-53. PubMed ID: 25818095
[TBL] [Abstract][Full Text] [Related]
4. Novel association between CD74 polymorphisms and hematologic toxicity in patients with NSCLC after platinum-based chemotherapy.
Tan X; Wu Q; Cai Y; Zhao X; Wang S; Gao Z; Yang Y; Li X; Qian J; Wang J; Su B; Chen H; Han B; Jiang G; Lu D
Clin Lung Cancer; 2014 Jan; 15(1):67-78.e12. PubMed ID: 24220096
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer.
Zhao W; Hu L; Xu J; Shen H; Hu Z; Ma H; Shu Y; Shao Y; Yin Y
Cancer Chemother Pharmacol; 2013 May; 71(5):1287-95. PubMed ID: 23479135
[TBL] [Abstract][Full Text] [Related]
6. Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients.
Han B; Gao G; Wu W; Gao Z; Zhao X; Li L; Qiao R; Chen H; Wei Q; Wu J; Lu D
Lung Cancer; 2011 May; 72(2):238-43. PubMed ID: 20943283
[TBL] [Abstract][Full Text] [Related]
7. Association of Wnt-Inducible Signaling Pathway Protein 1 Genetic Polymorphisms With Lung Cancer Susceptibility and Platinum-Based Chemotherapy Response.
Chen J; Yin JY; Li XP; Wang Y; Zheng Y; Qian CY; He H; Fang C; Wang Z; Zhang Y; Xiao L; Wang SY; Zhang W; Zhou HH; Liu ZQ
Clin Lung Cancer; 2015 Jul; 16(4):298-304.e1-2. PubMed ID: 25656821
[TBL] [Abstract][Full Text] [Related]
8. Prediction models for platinum-based chemotherapy response and toxicity in advanced NSCLC patients.
Yin JY; Li X; Li XP; Xiao L; Zheng W; Chen J; Mao CX; Fang C; Cui JJ; Guo CX; Zhang W; Gao Y; Zhang CF; Chen ZH; Zhou H; Zhou HH; Liu ZQ
Cancer Lett; 2016 Jul; 377(1):65-73. PubMed ID: 27126360
[TBL] [Abstract][Full Text] [Related]
9. Emerging roles of RAC1 in treating lung cancer patients.
Zou T; Mao X; Yin J; Li X; Chen J; Zhu T; Li Q; Zhou H; Liu Z
Clin Genet; 2017 Apr; 91(4):520-528. PubMed ID: 27790713
[TBL] [Abstract][Full Text] [Related]
10. WISP1 polymorphisms contribute to platinum-based chemotherapy toxicity in lung cancer patients.
Chen J; Yin J; Li X; Wang Y; Zheng Y; Qian C; Xiao L; Zou T; Wang Z; Liu J; Zhang W; Zhou H; Liu Z
Int J Mol Sci; 2014 Nov; 15(11):21011-27. PubMed ID: 25405734
[TBL] [Abstract][Full Text] [Related]
11. Lack of correlation between ERCC1 (C8092A) single nucleotide polymorphism and efficacy/toxicity of platinum based chemotherapy in Chinese patients with advanced non-small cell lung cancer.
KimCurran V; Zhou C; Schmid-Bindert G; Shengxiang R; Zhou S; Zhang L; Zhang J
Adv Med Sci; 2011; 56(1):30-8. PubMed ID: 21536539
[TBL] [Abstract][Full Text] [Related]
12. [Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Sun Y; Xu BH; Lin DX
Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):972-5. PubMed ID: 16061005
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms of BCL2 and BAX Genes Associate with Outcomes in Advanced Non-small cell lung cancer Patients treated with platinum-based Chemotherapy.
Peng Y; Wang L; Qing Y; Li C; Ren T; Li Q; Li M; Zhang S; Shan J; Wang G; Yang Z; Wang D
Sci Rep; 2015 Dec; 5():17766. PubMed ID: 26656462
[TBL] [Abstract][Full Text] [Related]
14. Correlation of MSH3 polymorphisms with response and survival in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.
Xu XL; Yao YL; Xu WZ; Feng JG; Mao WM
Genet Mol Res; 2015 Apr; 14(2):3525-33. PubMed ID: 25966119
[TBL] [Abstract][Full Text] [Related]
15. Age-related common miRNA polymorphism associated with severe toxicity in lung cancer patients treated with platinum-based chemotherapy.
Fang C; Li XP; Gong WJ; Wu NY; Tang J; Yin JY; Li X; Zhang W; Zhou HH; Liu ZQ
Clin Exp Pharmacol Physiol; 2017 Dec; 44 Suppl 1():21-29. PubMed ID: 27873337
[TBL] [Abstract][Full Text] [Related]
16. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.
Jin ZY; Zhao XT; Zhang LN; Wang Y; Yue WT; Xu SF
Genet Mol Res; 2014 Mar; 13(3):7617-25. PubMed ID: 24737519
[TBL] [Abstract][Full Text] [Related]
17. Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer.
Booton R; Ward T; Heighway J; Ashcroft L; Morris J; Thatcher N
J Thorac Oncol; 2006 Sep; 1(7):679-83. PubMed ID: 17409936
[TBL] [Abstract][Full Text] [Related]
18. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.
Gurubhagavatula S; Liu G; Park S; Zhou W; Su L; Wain JC; Lynch TJ; Neuberg DS; Christiani DC
J Clin Oncol; 2004 Jul; 22(13):2594-601. PubMed ID: 15173214
[TBL] [Abstract][Full Text] [Related]
19. Association of POLK polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients.
Shao M; Jin B; Niu Y; Ye J; Lu D; Han B
Cell Biochem Biophys; 2014 Nov; 70(2):1227-37. PubMed ID: 24948471
[TBL] [Abstract][Full Text] [Related]
20. Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer.
Provencio M; Camps C; Cobo M; De las Peñas R; Massuti B; Blanco R; Alberola V; Jimenez U; Delgado JR; Cardenal F; Tarón M; Ramírez JL; Sanchez A; Rosell R
Cancer Chemother Pharmacol; 2012 Dec; 70(6):883-90. PubMed ID: 23053267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
